New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
08:41 EDTSONC, LLY, FINL, FOLD, LULU, ARAY, AUO, FLOn The Fly: Pre-market Movers
HIGHER AFTER GUIDANCE: Eli Lilly (LLY), up 1.7%... ALSO HIGHER: Amicus Theraputics (FOLD), up 8.5% after announcing results from Phase 2 study... AU Optronics (AUO), up 4.7% after DigiTimes said company asked to join Amazon supply chain... LOWER AFTER EARNINGS/GUIDANCE: Finish Line (FINL), down 7%... Sonic (SONC), down 5%... Accuray (ARAY), down 25.5%... ALSO LOWER: Foot Locker (FL), down 2% after disappointing results, guidance of peer Finish Line... lululemon (LULU), down 3.9% after downgrade to Neutral at Credit Suisse.
News For FINL;FL;LULU;LLY;AUO;FOLD;SONC;ARAY From The Last 14 Days
Check below for free stories on FINL;FL;LULU;LLY;AUO;FOLD;SONC;ARAY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 16, 2014
07:54 EDTSONCSonic upgraded to Buy from Neutral at Sterne Agee
Subscribe for More Information
April 15, 2014
09:39 EDTLULUlululemon to host analyst day
Subscribe for More Information
07:01 EDTLULUlululemon can ease competition concerns at analyst day, says Canaccord
Subscribe for More Information
06:32 EDTLLYPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
06:13 EDTAUOAU Optronics and LG Display to mass produce 42.5-inch LCD panels, DigiTimes says
Subscribe for More Information
April 14, 2014
10:09 EDTSONCSonic mentioned cautiously by Off Wall Street
Subscribe for More Information
10:02 EDTLLYOn The Fly: Analyst Upgrade Summary
Acorda Therapeutics (ACOR) upgraded to Outperform from Market Perform at FBR Capital... Allegheny Technologies (ATI) upgraded to Neutral from Underperform at Sterne Agee... BP (BP) upgraded to Buy from Hold at Canaccord... Bloomin' Brands (BLMN) upgraded to Buy from Hold at Deutsche Bank... Boardwalk Pipeline (BWP) upgraded to Neutral from Underperform at BofA/Merrill... Boston Scientific (BSX) upgraded at BofA/Merrill... Charles Schwab (SCHW) upgraded to Buy from Neutral at UBS... Citigroup (C) upgraded to Hold from Sell at Rafferty Capital... Community Health (CYH) upgraded to Outperform from Perform at Oppenheimer... Eaton Vance (EV) upgraded to Neutral from Sell at Citigroup... Eli Lilly (LLY) upgraded to Hold from Underperform at Jefferies... F5 Networks (FFIV) upgraded to Buy from Hold at Stifel... HeartWare (HTWR) upgraded to Buy from Neutral at BTIG... Heartland Payment (HPY) upgraded to Hold from Sell at Stifel... Hyatt Hotels (H) upgraded to Outperform from Market Perform at FBR Capital... MasterCard (MA) upgraded to Outperform from Neutral at RW Baird... McDermott (MDR) upgraded to Neutral from Underweight at HSBC... Palo Alto (PANW) upgraded to Overweight at Stephens... PetroChina (PTR) upgraded to Neutral from Underperform at Credit Suisse... Seagate (STX) upgraded to Buy from Hold at Argus... Sensata (ST) upgraded to Buy from Neutral at Citigroup... Stryker (SYK) upgraded to Neutral from Reduce at SunTrust... TD Ameritrade (AMTD) upgraded to Buy from Neutral at UBS... TTM Technologies (TTMI) upgraded to Buy from Hold at Stifel... Transocean (RIG) upgraded to Hold from Sell at Deutsche Bank... VMware (VMW) upgraded to Outperform from Underperform at CLSA... Visa (V) upgraded to Outperform from Neutral at RW Baird... Yahoo (YHOO) upgraded to Buy from Neutral at SunTrust... Zimmer (ZMH) upgraded to Neutral from Reduce at SunTrust... bebe stores (BEBE) upgraded to Buy from Neutral at Janney Capital.
09:04 EDTLLYEli Lilly and Boehringer Ingelheim's NDA accepted by FDA
Subscribe for More Information
05:57 EDTLLYEli Lilly upgraded to Hold from Underperform at Jefferies
Subscribe for More Information
April 9, 2014
09:20 EDTFLBofA/Merrill's retail analysts hold an analyst/industry conference call
Subscribe for More Information
08:03 EDTLLYEli Lilly and T1D to partner in diabetes research collaboration
Subscribe for More Information
April 8, 2014
11:03 EDTLLYPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
10:03 EDTLLYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:21 EDTLLYEli Lilly to challenge verdict in Terrence Allen, et al. v. Takeda case
Subscribe for More Information
08:39 EDTLLYTakeda to challenge award of $6B in punitive damages, Lilly ordered to pay $3B
Takeda Pharmaceuticals (TKPYY) announced last night that in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America the jury found in favor of the plaintiffs and awarded $1.475M in compensatory damages. The allocation of liability was 75% Takeda and 25% Eli Lilly (LLY). The jury also awarded $6B in punitive damages from Takeda and $3B from co-defendant, Eli Lilly. “Takeda respectfully disagrees with the verdict and we intend to vigorously challenge this outcome through all available legal means, including possible post-trial motions and an appeal. We have empathy for the Allens, but we believe the evidence did not support a finding that ACTOS caused his bladder cancer. We also believe we demonstrated that Takeda acted responsibly with regard to ACTOS,” said Kenneth Greisman, senior vice president, general counsel, Takeda. Reference Link
08:26 EDTLLYEli Lilly upgraded at BMO Capital
Subscribe for More Information
06:24 EDTLLYEli Lilly upgraded to Market Perform from Underperform at BMO Capital
Subscribe for More Information
April 7, 2014
13:10 EDTLULUlululemon weekly volatility elevated into Analyst Day
Subscribe for More Information
07:38 EDTLULUlululemon reiterated as a Buy ahead of Analyst Day at Topeka
Topeka expects lululemon's April 17 Analyst Day to be a "very positive" event and reiterates its Buy rating and $70 price target ahead of the event. The analyst said the new CEO is on a marketing offensive as the store base expands worldwide and new heads of merchandising and sourcing are working to maintain a high quality, innovative product.
April 6, 2014
13:57 EDTLLYLilly to present data from bemaciclib as potential treatment for breast cancer
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use